Welcome!

News Feed Item

Preclinical Investigation Shows Ground-Breaking Results on Human Infections

RHEINBREITBACH, Germany, November 14, 2012 /PRNewswire/ --

Synthetic human-milk-oligosaccharides reduce the risk of infections caused by hazardous pathogens

Human-milk-oligosaccharides, an important component of human mother's milk, play a fundamental role in the protection of infants against viral and bacterial infection. Preclinical studies carried out by Jennewein Biotechnologie GmbH have now shown for the first time that synthetically produced functional sugars protect humans from infectious diseases. The investigations were conducted in collaboration with the University Children's Hospital Mannheim of Heidelberg University (GER).

In collaboration with the University Children's Hospital Mannheim of Heidelberg University, Jennewein Biotechnologie GmbH carried out extensive preclinical research to demonstrate for the first time that synthetic human-milk-oligosaccharides achieve the same protective effects as natural sugars in human breast milk. The study focused on the human-milk-oligosaccharides 2'-Fucosyllactose and 3-Fucosyllactose, which are present in human breast milk at levels of up to 3.5 grams per liter and are by far the most abundant human-milk-oligosaccharides.

The researchers at Mannheim (GER) tested the sugars on human cells using various pathogens. The results demonstrate a clear protective effect, i.e. the synthetic human-milk-oligosaccharides produced by Jennewein Biotechnologie GmbH successfully bind prevalent diarrhea causing pathogens such as Campylobacter jejuni, Escherichia coli and particular Salmonella species. Furthermore, the now available results reveal that these saccharides effectively inhibit the pneumonia causing pathogen Pseudomonas aeruginosa, which is together with E. coli and Staphylococcus aureus the most common pathogen causing nosocomial infections. Moreover, Pseudomonas aeruginosa infections can cause severe, life-threatening infections in patients with underlying immunodeficiency.

Human-milk-oligosaccharides not only inhibit gastrointestinal pathogens directly, they also provide at least two further major benefits. First, they have a prebiotic or bifidogenic effect, encouraging the growth of bifidobacteria that improve digestion and suppress pathogens to maintain a healthy microbiome. Second, up to 1% of these saccharides are absorbed into the blood, where they provide a systemic protection such as reducing the risk of infection of organs such as the lungs and meninges, for example. Although there is abundant evidence for the benefits of human-milk-oligosaccharides further research is required to understand the underlying mechanisms. Jennewein Biotechnologie GmbH has taken the lead in this research and is committed to the development of innovative products based on synthetic human-milk-oligosaccharides to reduce infection rates in infants and adults.

As emphasized Prof. Dr. Schroten, Director of the University Children's Hospital Mannheim of Heidelberg University, " this study represents asignificant milestone in the development of novel and effective non-interventional strategies to reduce the risk of human infections by pathogenic bacteria. In consideration of the continued growth of the world population and the increasing number of multidrug-resistant bacteria, this represents one of the key challenges of the 21st century."

The protective mechanism of human-milk-oligosaccharides

Mother's milk is seen as the "gold standard" for infant nutrition during the first few months of human life, not only reflecting the optimal balance of nutrients but also because of its ingredients with specific biological functions. Human-milk-oligosaccharides are the third most abundant solid component of breast milk, after lactose and fat which primarily serve as energy source. These human-milk-oligosaccharides are highly complex sugar molecules which are human specific and therefore can only be found in nature in this composition in human mother's milk.

Many scientific studies have shown that human-milk-oligosaccharides reduce the risk of infection by pathogens and have no adverse effects in humans. Soluble human-milk-oligosaccharides imitate sugar molecules that are found on the surface of all human cells to facilitate cell-to-cell communication. More than 70% of human pathogens - virus and bacteria - use these cell-surface sugar molecules to attach to, enter and infect cells. Thus, soluble human-milk-oligosaccharides in the gastrointestinal tract and in the blood act as decoys to prevent pathogens interacting with cells. Human pathogens will connect to these soluble saccharides "assuming" they connect to a host cell. The binding between pathogens and sugar molecules is irreversible and pathogens have no possibility to become resistant to soluble human-milk-oligosaccharides because they need to interact with the same molecules on the cell surface. Therefore, pathogens that do not bind to these sugars would be unable to bind to the cell surface either, and would lose their virulence.

Because human-milk-oligosaccharides have a specific role in the elimination of pathogens they are not used by human cells as an energy source. However, they retain the organoleptic properties of other sugars, i.e. they are soluble and sweet. This means that human-milk-oligosaccharides could be added to the diet in place of sucrose, for example, acting as sweeteners with no calorific value but also providing prebiotic benefits and protecting against infection.

Multiple applications for Fucosyllactose in human nutrition

The synthetic human-milk-oliogsacchrides produced by Jennewein Biotechnologie GmbH are presented as white, crystalline powders similar to sucrose, making them ideal as additives for use by the food processing industry to increase the health-promoting characteristics of innovative food products. In specialized areas, Jennewein Biotechnologie GmbH already cooperates with Pfizer Nutrition, one of the leading international infant food manufacturers. However, there are many other potential applications outside the field of infant nutrition, ranging from dairy products, breakfast cereals and beverages providing health benefits to special nutrition programs for professionals facing a high risk of infection, dietary supplements for travelers in disease-endemic areas, special diets for immunocompromized hospital patients to prevent nosocomial infections and therapeutic nutrition used to improve patients' clinical outcomes and quality of life.

About Jennewein Biotechnologie GmbH

Jennewein Biotechnologie GmbH is active in the field of industrial biotechnology and specializes in the production of complex sugar molecules using bio-organic synthesis. The main focus of the company is the production of ingredients for the food, personal care and pharmaceutical industries. Jennewein Biotechnology also produces molecules for research and development, as well as for diagnostics.

Jennewein Biotechnologie GmbH is a family-owned company, founded in 2005 with its headquarters in Rheinbreitbach (Rhineland-Palatinate, Germany). The company cooperates in research and development with leading universities and research institutes. Jennewein Biotechnologie GmbH received the Pionier-Geist award in 2007 from the Rhineland-Palatinate Ministry of Economics. The Federal Ministry of Education and Research supports Jennewein Biotechnologie GmbH in its research and development activities in the field of human-milk-oligosaccharides.

Further information

Further information about Jennewein Biotechnology GmbH, its products and graphical material can be obtained at http://www.jennewein-biotech.de or by writing to:  

Jennewein Biotechnologie GmbH
Maarweg 32
D-53619 Rheinbreitbach
Germany
Tel.:  +49-(0)2224-989-4502
Fax.:  +49-(0)2224-988-0854
EMail: [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Digital transformation has increased the pace of business creating a productivity divide between the technology haves and have nots. Managing financial information on spreadsheets and piecing together insight from numerous disconnected systems is no longer an option. Rapid market changes and aggressive competition are motivating business leaders to reevaluate legacy technology investments in search of modern technologies to achieve greater agility, reduced costs and organizational efficiencies. ...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
The taxi industry never saw Uber coming. Startups are a threat to incumbents like never before, and a major enabler for startups is that they are instantly “cloud ready.” If innovation moves at the pace of IT, then your company is in trouble. Why? Because your data center will not keep up with frenetic pace AWS, Microsoft and Google are rolling out new capabilities. In his session at 20th Cloud Expo, Don Browning, VP of Cloud Architecture at Turner, posited that disruption is inevitable for comp...
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, discussed how by using ne...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service.
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
@DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises - and delivering real results.
In his general session at 19th Cloud Expo, Manish Dixit, VP of Product and Engineering at Dice, discussed how Dice leverages data insights and tools to help both tech professionals and recruiters better understand how skills relate to each other and which skills are in high demand using interactive visualizations and salary indicator tools to maximize earning potential. Manish Dixit is VP of Product and Engineering at Dice. As the leader of the Product, Engineering and Data Sciences team at D...
DXWorldEXPO LLC announced today that All in Mobile, a mobile app development company from Poland, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. All In Mobile is a mobile app development company from Poland. Since 2014, they maintain passion for developing mobile applications for enterprises and startups worldwide.
Both SaaS vendors and SaaS buyers are going “all-in” to hyperscale IaaS platforms such as AWS, which is disrupting the SaaS value proposition. Why should the enterprise SaaS consumer pay for the SaaS service if their data is resident in adjacent AWS S3 buckets? If both SaaS sellers and buyers are using the same cloud tools, automation and pay-per-transaction model offered by IaaS platforms, then why not host the “shrink-wrapped” software in the customers’ cloud? Further, serverless computing, cl...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors!